(Q37359517)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

4 references

24 July 2020

13 November 2020

28 January 2021

31 January 2021

Is mTOR inhibition a systemic treatment for tuberous sclerosis? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

10 references

14 March 2019

3 April 2019

22 April 2019

25 April 2019

25 June 2019

28 September 2019

11 November 2019

24 July 2020

13 November 2020

31 January 2021

1 reference

28 September 2019

1 reference

11 November 2019

1 reference

24 July 2020

1 reference

13 November 2020

Serine/threonine-protein kinase TOR

1 reference

28 January 2021

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Antonella Coniglio

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Francesco Garaci

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Paolo Curatolo

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

17 September 2013

12 references

14 March 2019

3 April 2019

22 April 2019

25 April 2019

25 June 2019

28 September 2019

11 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

24 July 2020

13 November 2020

28 January 2021

31 January 2021

Italian Journal of Paediatrics

12 references

14 March 2019

3 April 2019

22 April 2019

25 April 2019

25 June 2019

28 September 2019

11 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

24 July 2020

13 November 2020

28 January 2021

31 January 2021

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 2.0 Generic

22 February 2020

copyright license

11 references

14 March 2019

3 April 2019

22 April 2019

25 April 2019

25 June 2019

28 September 2019

11 November 2019

24 July 2020

13 November 2020

28 January 2021

on focus list of Wikimedia project

31 January 2021

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

mTOR Inhibitors in Tuberous Sclerosis Complex.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

A pulse rapamycin therapy for infantile spasms and associated cognitive decline

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Efficacy and safety of sirolimus in lymphangioleiomyomatosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

The natural history of epilepsy in tuberous sclerosis complex

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Rapamycin reduces seizure frequency in tuberous sclerosis complex

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Recent advances in neurobiology of Tuberous Sclerosis Complex.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Rapamycin: something old, something new, sometimes borrowed and now renewed

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

The tuberous sclerosis complex

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Increased brain apparent diffusion coefficient in tuberous sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Causes of Death in Patients With Tuberous Sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Regression of a cardiac rhabdomyoma in a patient receiving everolimus

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Early control of seizures improves long-term outcome in children with tuberous sclerosis complex

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848592

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

2 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1824-7288-39-57

The cutaneous features of tuberous sclerosis: a population study

21 January 2018

1 reference

12 December 2020

Cognitive impairment in tuberous sclerosis complex is a multifactorial condition

1 reference

12 December 2020

Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol

1 reference

12 December 2020

Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex

1 reference

12 December 2020

Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin

1 reference

12 December 2020

Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients

1 reference

12 December 2020

Epidemiology of tuberous sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1186/1824-7288-39-57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

22 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

24044547

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24044547%20AND%20SRC:MED&resulttype=core&format=json